Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06455384 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Site details revised at 2 of 3 sitesv4
  2. Notable Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 1, 2025 to Mar 2027 · Start date changed from estimate of Sep 1, 2024 to Oct 28, 2025 · Study sites: 2 to 3 · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Dec 1, 2025 to Mar 2027
    • Start date changed from estimate of Sep 1, 2024 to Oct 28, 2025
    • Study sites: 2 to 3
    • Completion date: Jul 1, 2026 to Jul 2027
  3. Notable Start date: Jul 1, 2024 to Sep 1, 2024 Enrollment target: 140 to 170 · Study sites: 3 to 2 · Secondary endpoints: details revised at 7 of 17 entries · 2 morev2 Show 5 more changesShow less
    • Enrollment target: 140 to 170
    • Study sites: 3 to 2
    • Secondary endpoints: details revised at 7 of 17 entries
    • Eligibility criteria expanded, about 2 words
    • Study description shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
730 trials monitored
See 45 trials at risk
Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.
Trial Details
NCT Number NCT06455384
Lead Sponsor Unity Health Toronto
Conditions Cardiac Conditions, Connective Tissue Diseases, Retinal Disease, Epilepsy in Children, Neurodevelopmental Disorders, Cancer, Polyposis
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov